SCN1A Sequencing, Full Gene

CPT: 81407
Print Share

Synonyms

  • Dravet Syndrome, FEB3

Test Includes

This test covers all coding nucleotides of gene SCN1A, plus at least two and typically 20 flanking intronic nucleotides upstream and downstream of each coding exon, covering the conserved donor and acceptor splice sites, as well as typically 20 flanking nucleotides in the 5' and 3' UTR.


Expected Turnaround Time

24 - 28 days


Related Documents

For more information, please view the literature below.

SCN1A-related Seizure Disorders Genetic Testing Patient Flyer


    Specimen Requirements


    Specimen

    Whole blood


    Volume

    7 mL


    Minimum Volume

    3 mL


    Container

    Lavender-top (EDTA) tube or yellow-top (ACD) tube


    Storage Instructions

    Maintain at room temperature or refrigerate at 4°C.


    Causes for Rejection

    Frozen or hemolyzed specimen; quantity not sufficient for analysis; improper container


    Test Details


    Use

    Confirms a diagnosis of a SCN1A-related seizure disorder, including but not limited to severe myoclonic epilepsy of infancy (SMEI, also known as Dravet Syndrome), intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalize epilepsy with febrile seizures plus (GEFS+).


    Limitations

    This method does not reliably detect mosaic variants; large deletions; large duplications, inversions, or other rearrangements; deep intronic variants or variants outside of the regions targeted by this analysis. It may be affected by allele-dropout, it may not allow determination of the exact numbers of T/A or microsatellite repeats, and it does not allow any conclusion as to whether two heterozygous variants are present on the same or on different chromosome copies.

    Results of this test are for investigational purposes only. The performance characteristics of this assay have been determined by LabCorp. The result should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.


    Methodology

    DNA sequencing


    Additional Information

    SCN1A-related seizure disorders encompass a spectrum of autosomal dominant disorders that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end. Less commonly observed phenotypes include myoclonic-astatic epilepsy (MAE or Doose syndrome), Lennox-Gastaut syndrome (LGS), infantile spasms, and vaccine-related encephalopathy and seizures. Individuals with seizures on the more severe end of the spectrum often carry a de novo pathogenic variant while individuals on the milder end of the spectrum often have an inherited pathogenic variant. In addition, the clinical presentation of family members carrying the same pathogenic SCN1A variant can vary. Consequently, testing combined with a detailed clinical history is recommended for the parents of any child with a SCN1A pathogenic variant or variant of uncertain significance.


    References

    Claes L, Ceulemans B, Audenaert D, et al. De Novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy, Hum Mutat. 2003 Jun; 21(6):615-621. 12754708
    Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, Harkin LA. SCN1A mutations and epilepsy. Hum Mutat. 2005 Jun; 25(6):535-542. 15880351
    National Institute of Neurological Disorder and Seizures. Seizures and Epilepsy: Hope Through Research. National Institutes of Health Publications N° 04-156, originally published May 2004; updated March 2, 2006. Available at: http://www.ninds.nih.gov/disorders/epilepsy/detail_epilepsy.htm

    LOINC® Map

    Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
    511236 SCN1A DNA Sequencing 41765-9 511237 SCN1A DNA Sequencing 41765-9

    For Providers

    Please login to order a test

    Order a Test

    © 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

    CPT Statement/Profile Statement

    The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf